간암 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Liver Cancer Diagnostic Market size is expected to reach USD 20.64 Billion in 2034 from USD 10.96 Billion (2025) growing at a CAGR of 7.29% during 2026-2034.

The liver cancer diagnostic market is experiencing significant growth, driven by the increasing incidence of liver cancer and the rising awareness of early detection and diagnosis. As the global burden of liver cancer continues to escalate, fueled by factors such as hepatitis infections, alcohol consumption, and obesity, the demand for effective diagnostic solutions is surging. Innovations in imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, are enhancing the accuracy and sensitivity of liver cancer detection, enabling healthcare providers to identify tumors at earlier stages when treatment options are more effective.

Moreover, advancements in biomarker research are transforming the liver cancer diagnostic landscape. The identification of specific biomarkers associated with liver cancer is paving the way for the development of non-invasive blood tests that can aid in early diagnosis and monitoring of disease progression. These tests not only improve patient comfort but also reduce the need for invasive procedures, making them an attractive option for both patients and healthcare providers. The growing emphasis on personalized medicine is further driving the demand for advanced diagnostic tools that can tailor treatment strategies based on individual patient profiles.

Additionally, the increasing focus on preventive healthcare and screening programs is contributing to the growth of the liver cancer diagnostic market. As healthcare organizations implement routine screening for high-risk populations, the demand for reliable diagnostic solutions is expected to rise. The collaboration between research institutions, diagnostic companies, and healthcare providers is fostering innovation and accelerating the development of new diagnostic technologies. In summary, the liver cancer diagnostic market is set for robust growth, characterized by technological advancements, a focus on early detection, and a commitment to improving patient outcomes through effective diagnostic solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Laboratory Tests
• Imaging
• Endoscopy
• Biopsy
• Others

By End-use

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & CRO Laboratories

COMPANIES PROFILED

• Abbott Laboratories, F HoffmannLa Roche Ltd, Qiagen NV, Thermo Fisher Scientific, Inc, Siemens Healthineers, Becton Dickinson Company, Illumina, Inc, Koninklijke Philips NV, Epigenomics AG, Fujifilm Medical Systems USA, Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Laboratory Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Endoscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals & Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pharmaceutical & CRO Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Test Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Test Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Test Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Test Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Test Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL LIVER CANCER DIAGNOSTIC INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott Laboratories
  • 8.2.2 F. Hoffmann-La Roche Ltd
  • 8.2.3 Qiagen N.V
  • 8.2.4 Thermo Fisher ScientificInc
  • 8.2.5 Siemens Healthineers
  • 8.2.6 Becton Dickinson & Company
  • 8.2.7 IlluminaInc
  • 8.2.8 Koninklijke Philips N.V
  • 8.2.9 Epigenomics AG
  • 8.2.10 Fujifilm Medical Systems U.S.A.Inc